🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/10/1994 | 7,13 | 7,13 | 6,75 | 7,06 | +3,67% | 5,26% | 13.800 |
| 07/10/1994 | 7,00 | 7,00 | 6,75 | 6,81 | -1,80% | 3,57% | 140.200 |
| 06/10/1994 | 6,88 | 7,06 | 6,88 | 6,94 | -0,89% | 2,73% | 108.200 |
| 05/10/1994 | 7,25 | 7,25 | 6,88 | 7,00 | -0,88% | 5,17% | 32.200 |
| 04/10/1994 | 7,25 | 7,25 | 7,00 | 7,06 | +0,00% | 3,45% | 17.800 |
| 03/10/1994 | 7,25 | 7,25 | 7,00 | 7,06 | -0,88% | 3,45% | 10.400 |
| 30/09/1994 | 7,25 | 7,25 | 7,00 | 7,13 | +0,88% | 3,45% | 377.600 |
| 29/09/1994 | 7,50 | 7,50 | 7,00 | 7,06 | -3,42% | 6,67% | 133.600 |
| 28/09/1994 | 7,13 | 7,31 | 7,13 | 7,31 | +0,86% | 2,63% | 6.600 |
| 27/09/1994 | 7,38 | 7,50 | 7,13 | 7,25 | -2,52% | 5,08% | 77.200 |
| 26/09/1994 | 7,63 | 7,63 | 7,38 | 7,44 | -4,03% | 3,28% | 109.400 |
| 23/09/1994 | 7,38 | 7,75 | 7,38 | 7,75 | +3,33% | 5,08% | 538.200 |
| 22/09/1994 | 7,38 | 7,75 | 7,00 | 7,50 | +1,69% | 10,17% | 288.400 |
| 21/09/1994 | 7,13 | 7,38 | 7,00 | 7,38 | +1,72% | 5,26% | 75.800 |
| 20/09/1994 | 7,38 | 7,38 | 7,13 | 7,25 | +1,75% | 3,39% | 30.200 |
| 19/09/1994 | 7,25 | 7,25 | 7,00 | 7,13 | +0,00% | 3,45% | 38.600 |
| 16/09/1994 | 7,50 | 7,50 | 7,00 | 7,13 | -3,39% | 6,67% | 67.000 |
| 15/09/1994 | 7,50 | 7,75 | 7,25 | 7,38 | -4,84% | 6,67% | 116.600 |
| 14/09/1994 | 7,38 | 7,75 | 7,25 | 7,75 | +6,90% | 6,78% | 48.600 |
| 13/09/1994 | 7,38 | 7,38 | 6,88 | 7,25 | -4,92% | 6,78% | 254.600 |
| 12/09/1994 | 7,50 | 7,75 | 7,50 | 7,63 | -1,61% | 3,33% | 53.400 |
| 09/09/1994 | 7,75 | 7,75 | 7,38 | 7,75 | +5,08% | 4,84% | 58.000 |
| 08/09/1994 | 7,25 | 7,75 | 7,06 | 7,38 | +0,00% | 9,48% | 226.400 |
| 07/09/1994 | 7,38 | 7,50 | 7,19 | 7,38 | -1,67% | 4,24% | 30.800 |
| 06/09/1994 | 7,00 | 7,50 | 7,00 | 7,50 | +3,90% | 7,14% | 11.800 |
| 02/09/1994 | 7,25 | 7,25 | 7,00 | 7,22 | +5,00% | 3,45% | 28.800 |
| 01/09/1994 | 6,88 | 7,25 | 6,88 | 6,88 | -4,35% | 5,45% | 67.800 |
| 31/08/1994 | 6,88 | 7,25 | 6,88 | 7,19 | +1,77% | 5,45% | 3.400 |
| 30/08/1994 | 7,25 | 7,25 | 6,88 | 7,06 | -0,88% | 5,17% | 6.400 |
| 29/08/1994 | 7,25 | 7,50 | 6,88 | 7,13 | -2,56% | 8,62% | 95.600 |